Literature DB >> 33761214

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.

Benoit Rousseau1, Michael B Foote1, Steven B Maron1, Bill H Diplas1, Steve Lu2, Guillem Argilés3, Andrea Cercek3, Luis A Diaz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33761214      PMCID： PMC8403269          DOI： 10.1056/NEJMc2031965

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

2.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Authors:  Robert M Samstein; Chung-Han Lee; Alexander N Shoushtari; Matthew D Hellmann; Ronglai Shen; Yelena Y Janjigian; David A Barron; Ahmet Zehir; Emmet J Jordan; Antonio Omuro; Thomas J Kaley; Sviatoslav M Kendall; Robert J Motzer; A Ari Hakimi; Martin H Voss; Paul Russo; Jonathan Rosenberg; Gopa Iyer; Bernard H Bochner; Dean F Bajorin; Hikmat A Al-Ahmadie; Jamie E Chaft; Charles M Rudin; Gregory J Riely; Shrujal Baxi; Alan L Ho; Richard J Wong; David G Pfister; Jedd D Wolchok; Christopher A Barker; Philip H Gutin; Cameron W Brennan; Viviane Tabar; Ingo K Mellinghoff; Lisa M DeAngelis; Charlotte E Ariyan; Nancy Lee; William D Tap; Mrinal M Gounder; Sandra P D'Angelo; Leonard Saltz; Zsofia K Stadler; Howard I Scher; Jose Baselga; Pedram Razavi; Christopher A Klebanoff; Rona Yaeger; Neil H Segal; Geoffrey Y Ku; Ronald P DeMatteo; Marc Ladanyi; Naiyer A Rizvi; Michael F Berger; Nadeem Riaz; David B Solit; Timothy A Chan; Luc G T Morris
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

3.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Authors:  Aurélien Marabelle; Marwan Fakih; Juanita Lopez; Manisha Shah; Ronnie Shapira-Frommer; Kazuhiko Nakagawa; Hyun Cheol Chung; Hedy L Kindler; Jose A Lopez-Martin; Wilson H Miller; Antoine Italiano; Steven Kao; Sarina A Piha-Paul; Jean-Pierre Delord; Robert R McWilliams; David A Fabrizio; Deepti Aurora-Garg; Lei Xu; Fan Jin; Kevin Norwood; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2020-09-10       Impact factor: 41.316
  3 in total
  31 in total

Review 1.  Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors:  Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal:  Nat Rev Cancer       Date:  2021-08-10       Impact factor: 60.716

2.  Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

Authors:  Daniel J McGrail; Patrick G Pilié; Hui Dai; Truong Nguyen Anh Lam; Yulong Liang; Leonie Voorwerk; Marleen Kok; Xiang H-F Zhang; Jeffrey M Rosen; Amy B Heimberger; Christine B Peterson; Eric Jonasch; Shiaw-Yih Lin
Journal:  Sci Transl Med       Date:  2021-10-27       Impact factor: 17.956

Review 3.  Biomarkers for immune checkpoint inhibitors in solid tumors.

Authors:  Vidit Kapoor; William James Kelly
Journal:  Clin Transl Oncol       Date:  2022-09-14       Impact factor: 3.340

Review 4.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.

Authors:  Zhaohui Jin; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

5.  Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.

Authors:  Shiro Takamatsu; Junzo Hamanishi; J B Brown; Ken Yamaguchi; Koji Yamanoi; Kosuke Murakami; Osamu Gotoh; Seiichi Mori; Masaki Mandai; Noriomi Matsumura
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

6.  FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.

Authors:  Leigh Marcus; Lola A Fashoyin-Aje; Martha Donoghue; Mengdie Yuan; Lisa Rodriguez; Pamela S Gallagher; Reena Philip; Soma Ghosh; Marc R Theoret; Julia A Beaver; Richard Pazdur; Steven J Lemery
Journal:  Clin Cancer Res       Date:  2021-06-03       Impact factor: 13.801

Review 7.  Toward personalized treatment approaches for non-small-cell lung cancer.

Authors:  Meina Wang; Roy S Herbst; Chris Boshoff
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

8.  Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.

Authors:  Laura S Graham; Colin C Pritchard; Michael T Schweizer
Journal:  Clin Cancer Res       Date:  2021-09-27       Impact factor: 13.801

Review 9.  POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.

Authors:  Luigi Magrin; Daniele Fanale; Chiara Brando; Antonio Russo; Viviana Bazan; Alessia Fiorino; Lidia Rita Corsini; Roberta Sciacchitano; Clarissa Filorizzo; Alessandra Dimino
Journal:  Oncogene       Date:  2021-08-06       Impact factor: 9.867

Review 10.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.